Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 3/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.33 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209652 | 0.83 | KDM1A (0.46) | KDM1AS1PR4HRH4HCAR1NPFFR1 | |
| SCHEMBL12879057 | 0.79 | SMN1; SMN2 (0.39) | CCR2ARNOTUM | |
| SCHEMBL27075757 | 0.79 | IDO1 (0.42) | CCR2HCAR1ARNOTUM | |
| SCHEMBL22904716 | 0.79 | CES2 (0.46) | CCR2ARALDH1A1 | |
| SCHEMBL31560015 | 0.79 | AR (0.41) | KDM1AS1PR4CCR2HRH4HCAR1 | |
| SCHEMBL2065678 | 0.79 | DDR1 (0.42) | KDM1AS1PR4CCR2HRH4HCAR1 | |
| SCHEMBL2645981 | 0.78 | ALOX15 (0.42) | CCR2ALDH1A1 | |
| SCHEMBL25761353 | 0.78 | CCR2 (0.50) | CCR2NOTUM | |
| SCHEMBL5878833 | 0.78 | AR (0.42) | CCR2ARNOTUMALDH1A1 | |
| SCHEMBL382091 | 0.78 | GAA (0.55) | CCR2ARNOTUMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| EP-3089974-B1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | IPSEN PHARMA SAS (FR) | 2019-02-20 | — | — | EP | disclosed |
| EP-3089975-B1 | NOVEL IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES | IPSEN PHARMA SAS (FR) | 2018-06-06 | — | — | EP | disclosed |
| US-9975880-B2 | Imidazolidine-2,4-dione dervatives | IPSEN PHARMA S.A.S. (FR) | 2018-05-22 | — | — | US | disclosed |
| US-9676752-B2 | Imidazolidine-2,4-dione derivatives | IPSEN PHARMA S.A.S. (FR) | 2017-06-13 | — | — | US | disclosed |
| EP-3089974-A1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | IPSEN PHARMA S.A.S. (FR) | 2016-11-09 | — | — | EP | disclosed |
| EP-3089975-A1 | NOVEL IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES | IPSEN PHARMA S.A.S. (FR) | 2016-11-09 | — | — | EP | disclosed |
| US-20160318908-A1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | IPSEN PHARMA S.A.S. (FR) | 2016-11-03 | — | — | US | disclosed |
| WO-2004089885-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | WO | disclosed |
| EP-1169312-B1 | GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-20040014968-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED THOMAS (US) | 2004-01-22 | — | — | US | disclosed |
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| CN-1411453-A | Trans olefinic glucokinase activators | HOFFMANN LA ROCHE (CH) | 2003-04-16 | — | — | CN | disclosed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | disclosed |
| EP-1169312-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-09 | — | — | EP | disclosed |
| US-6320050-B1 | 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. | HOFFMANN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-11-08 | — | — | US | disclosed |
| WO-2000058293-A2 | GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014968-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | KDM1A 3767/4885S1PR4 4271/4885CCR2 3563/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | KDM1A 1279/4885S1PR4 3899/4885CCR2 218/4885 |
| US-20010039344-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | KDM1A 4344/4885S1PR4 4202/4885CCR2 3474/4885 |
| US-20160318908-A1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | MKI67, CCNI, CDKN1A | KDM1A 2015/4885S1PR4 4352/4885CCR2 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.